Atopic Dermatitis is the most prevalent type of eczema. The drug we developed to treat the inflammation and itch associated with the disease is currently being tested in human clinical trials.
UC is a chronic disease with no cure. Our work focuses on discovering safer and more effective small-molecule treatments, and we have identified and validated a novel AI-generated target with no previous link to UC.
GBM is a complex, aggressive and lethal brain tumour. Our work focuses on mechanisms that may contribute to the progression and relapse of the disease, and we advanced one of the most promising candidates through to lead optimisation.
ALS is a progressive and ultimately fatal neurodegenerative disease. Our two programmes aim to identify targets to treat ALS, and we have progressed two targets to candidate seeking and lead optimization.
By fusing artificial and human intelligence, we empower scientists to uncover new relationships between diseases and symptoms, drugs and their effects and the subgroups of patients who will respond to treatment.